These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 31166114)

  • 1. YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib.
    Garmendia I; Pajares MJ; Hermida-Prado F; Ajona D; Bértolo C; Sainz C; Lavín A; Remírez AB; Valencia K; Moreno H; Ferrer I; Behrens C; Cuadrado M; Paz-Ares L; Bustelo XR; Gil-Bazo I; Alameda D; Lecanda F; Calvo A; Felip E; Sánchez-Céspedes M; Wistuba II; Granda-Diaz R; Rodrigo JP; García-Pedrero JM; Pio R; Montuenga LM; Agorreta J
    Am J Respir Crit Care Med; 2019 Oct; 200(7):888-899. PubMed ID: 31166114
    [No Abstract]   [Full Text] [Related]  

  • 2. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
    Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. YES1 as a potential target to overcome drug resistance in EGFR-deregulated non-small cell lung cancer.
    Kook E; Lee J; Kim DH
    Arch Toxicol; 2024 May; 98(5):1437-1455. PubMed ID: 38443724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. YES1 activation induces acquired resistance to neratinib in HER2-amplified breast and lung cancers.
    Takeda T; Yamamoto H; Suzawa K; Tomida S; Miyauchi S; Araki K; Nakata K; Miura A; Namba K; Shien K; Soh J; Shien T; Kitamura Y; Sendo T; Toyooka S
    Cancer Sci; 2020 Mar; 111(3):849-856. PubMed ID: 31856375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. YES1 Is a Druggable Oncogenic Target in SCLC.
    Redin E; Garrido-Martin EM; Valencia K; Redrado M; Solorzano JL; Carias R; Echepare M; Exposito F; Serrano D; Ferrer I; Nunez-Buiza A; Garmendia I; García-Pedrero JM; Gurpide A; Paz-Ares L; Politi K; Montuenga LM; Calvo A
    J Thorac Oncol; 2022 Dec; 17(12):1387-1403. PubMed ID: 35988891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LYN expression predicts the response to dasatinib in a subpopulation of lung adenocarcinoma patients.
    Kim YJ; Hong S; Sung M; Park MJ; Jung K; Noh KW; Oh DY; Lee MS; Oh E; Shin YK; Choi YL
    Oncotarget; 2016 Dec; 7(50):82876-82888. PubMed ID: 27756880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. YES1: A Novel Therapeutic Target and Biomarker in Cancer.
    Garmendia I; Redin E; Montuenga LM; Calvo A
    Mol Cancer Ther; 2022 Sep; 21(9):1371-1380. PubMed ID: 35732509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapamycin Enhances the Anti-Cancer Effect of Dasatinib by Suppressing Src/PI3K/mTOR Pathway in NSCLC Cells.
    Chen B; Xu X; Luo J; Wang H; Zhou S
    PLoS One; 2015; 10(6):e0129663. PubMed ID: 26061184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development.
    Fujihara M; Shien T; Shien K; Suzawa K; Takeda T; Zhu Y; Mamori T; Otani Y; Yoshioka R; Uno M; Suzuki Y; Abe Y; Hatono M; Tsukioki T; Takahashi Y; Kochi M; Iwamoto T; Taira N; Doihara H; Toyooka S
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SRC Family Kinase Inhibition Targets YES1 and YAP1 as Primary Drivers of Lung Cancer and as Mediators of Acquired Resistance to ALK and Epidermal Growth Factor Receptor Inhibitors.
    Sato H; Kubota D; Qiao H; Jungbluth A; Rekhtman N; Schoenfeld AJ; Yu HA; Riely GJ; Toyooka S; Lovly CM; Paik P; Ladanyi M; Fan PD
    JCO Precis Oncol; 2022 Aug; 6():e2200088. PubMed ID: 35952318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway.
    Wen Q; Wang W; Luo J; Chu S; Chen L; Xu L; Zang H; Alnemah MM; Ma J; Fan S
    Oncotarget; 2016 May; 7(19):27787-801. PubMed ID: 27050281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.
    Johnson FM; Saigal B; Talpaz M; Donato NJ
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6924-32. PubMed ID: 16203784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquired resistance mechanisms to afatinib in HER2-amplified gastric cancer cells.
    Yoshioka T; Shien K; Takeda T; Takahashi Y; Kurihara E; Ogoshi Y; Namba K; Torigoe H; Sato H; Tomida S; Yamamoto H; Soh J; Fujiwara T; Toyooka S
    Cancer Sci; 2019 Aug; 110(8):2549-2557. PubMed ID: 31162771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The inhibition of SRC family kinase suppresses pancreatic cancer cell proliferation, migration, and invasion.
    Je DW; O YM; Ji YG; Cho Y; Lee DH
    Pancreas; 2014 Jul; 43(5):768-76. PubMed ID: 24763074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
    Takeda T; Yamamoto H; Kanzaki H; Suzawa K; Yoshioka T; Tomida S; Cui X; Murali R; Namba K; Sato H; Torigoe H; Watanabe M; Shien K; Soh J; Asano H; Tsukuda K; Kitamura Y; Miyoshi S; Sendo T; Toyooka S
    PLoS One; 2017; 12(2):e0171356. PubMed ID: 28158234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of downstream signaling cascades of ACK1 and prognostic classifiers in non-small cell lung cancer.
    Zhu J; Liu Y; Zhao M; Cao K; Ma J; Peng S
    Aging (Albany NY); 2021 Jan; 13(3):4482-4502. PubMed ID: 33495411
    [No Abstract]   [Full Text] [Related]  

  • 17. IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells.
    Lu H; Wang L; Gao W; Meng J; Dai B; Wu S; Minna J; Roth JA; Hofstetter WL; Swisher SG; Fang B
    Mol Cancer Ther; 2013 Dec; 12(12):2864-73. PubMed ID: 24130049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds.
    Huang Y; Chen Y; Mei Q; Chen Y; Yu S; Xia S
    Oncol Rep; 2013 Jun; 29(6):2486-92. PubMed ID: 23525575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.
    Zhang J; Zhang L; Su X; Li M; Xie L; Malchers F; Fan S; Yin X; Xu Y; Liu K; Dong Z; Zhu G; Qian Z; Tang L; Schöttle J; Zhan P; Ji Q; Kilgour E; Smith PD; Brooks AN; Thomas RK; Gavine PR
    Clin Cancer Res; 2012 Dec; 18(24):6658-67. PubMed ID: 23082000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A deuterated analog of dasatinib disrupts cell cycle progression and displays anti-non-small cell lung cancer activity in vitro and in vivo.
    Ling C; Chen G; Chen G; Zhang Z; Cao B; Han K; Yin J; Chu A; Zhao Y; Mao X
    Int J Cancer; 2012 Nov; 131(10):2411-9. PubMed ID: 22362357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.